Enhancing Prostate Cancer Genomics with AI-Powered Morphometric Analysis October 23, 2025 By Myriad Oncology™ As AI becomes more widely used in medicine, prostate cancer is emerging as one of the areas where its impact is most tangible. In path... Continue Reading
Using Prostate Cancer Gene Testing to Guide Treatment Decisions: Insights as We Head into 2026 October 1, 2025 By Dr. Christopher Lee, Cancer Care Northwest As clinicians caring for patients with prostate cancer, we all hear the question asked frequently of us “wha... Continue Reading
New Guidelines from AUA and ASTRO Support Inclusion of Genomic Testing in Localized Prostate Cancer May 17, 2022 By Thomas Slavin, M.D., chief medical officer, Myriad Genetics According to the American Cancer Society, in 2022 more than 268,000 men in the United S... Continue Reading
Precision Medicine in Prostate Cancer: How Genetic Testing Makes a Difference December 15, 2021 Back when scientists sequenced a human genome for the first time — a years-long project that took billions of dollars — they were in part motivated by the p... Continue Reading
Genetic Testing Can Help Men with Prostate Cancer Receive the Right Treatment September 1, 2018 September is Prostate Cancer Awareness Month. According the American Cancer Society, more than 165,000 men will be diagnosed with prostate cancer this year, and... Continue Reading
Men’s Health Month and Myriad’s Prolaris Test June 12, 2017 June is Men’s Health Month and it’s important to help generate awareness on education for early detection of Men’s health issues, such as prostate cance... Continue Reading
Myriad’s Prolaris Data Spikes Interest in Prognostic Prostate Cancer Testing July 2, 2013 Data recently presented by Myriad Genetics’ prostate cancer prognostic test Prolaris is getting healthcare professionals and patients interested in learning ... Continue Reading
Myriad’s Prolaris(R) Test Predicts Risk of Prostate Cancer Recurrence in Fourth Peer Reviewed Study March 6, 2013 SALT LAKE CITY, March 5, 2013 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a study published in the Journal of Clinical Oncolo... Continue Reading